Vericel Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that CFO Joe Mara will present at the H.C. Wainwright Virtual Global Life Sciences Conference. The presentation will provide a company overview and will be accessible via webcast on March 9, 2021, at 7:00 a.m. ET. Vericel specializes in advanced therapies for sports medicine and severe burns, marketing two major products: MACI^® for cartilage repair and Epicel^® for skin replacement in burn patients. The company also holds rights to NexoBrid^®, aimed at severe thermal burn debridement.

Positive

• CFO Joe Mara presenting at a prominent global life sciences conference, providing visibility.
• Continued focus on advanced therapies for sports medicine and severe burn care.

Negative

• None.

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Joe Mara, Chief Financial Officer, will present the latest company overview at the H.C. Wainwright Virtual Global Life Sciences Conference. The conference is being conducted in a virtual format and a webcast of the presentation will become available on Tuesday, March 9, 2021, at 7:00 a.m. Eastern Time.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 617-588-5666

FAQ

What will Joe Mara discuss at the H.C. Wainwright Conference for VCEL?

Joe Mara will present an overview of Vericel Corporation.

When will the VCEL presentation be available for viewing?

The presentation will be available via webcast on March 9, 2021, at 7:00 a.m. ET.

What products does Vericel Corporation market?

Vericel markets MACI^® for cartilage repair and Epicel^® for treating severe burns.

What is NexoBrid^®?

NexoBrid^® is a biological product for the debridement of severe thermal burns.